BioNTechBNTX
BNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,772
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $373M | Put options by funds: $269M
31% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 49
10% more capital invested
Capital invested by funds: $5.24B [Q3] → $5.78B (+$544M) [Q4]
2.74% more ownership
Funds ownership: 18.6% [Q3] → 21.34% (+2.74%) [Q4]
2% more funds holding
Funds holding: 293 [Q3] → 300 (+7) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 85
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$139
41%
upside
Avg. target
$149
51%
upside
High target
$171
74%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 16% 1-year accuracy 28 / 172 met price target | 47%upside $145 | Buy Maintained | 1 Apr 2025 |
Citigroup Geoff Meacham 36% 1-year accuracy 12 / 33 met price target | 47%upside $145 | Buy Initiated | 13 Mar 2025 |
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target | 41%upside $139 | Overweight Maintained | 11 Mar 2025 |
Canaccord Genuity John Newman 12% 1-year accuracy 3 / 26 met price target | 74%upside $171 | Buy Maintained | 11 Mar 2025 |
BMO Capital Etzer Darout 15% 1-year accuracy 5 / 33 met price target | 45%upside $143 | Outperform Maintained | 11 Mar 2025 |
Financial journalist opinion
Based on 9 articles about BNTX published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
Investors Business Daily
1 week ago
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
Negative
CNBC Television
2 weeks ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Negative
Fast Company
2 weeks ago
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Negative
New York Post
2 weeks ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Negative
CNBC
2 weeks ago
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Negative
Reuters
2 weeks ago
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments.
Positive
Market Watch
3 weeks ago
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
Neutral
GlobeNewsWire
4 weeks ago
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Metastatic Melanoma. Refractory Metastatic Melanoma Emerging Drugs Chapters This segment of the Refractory Metastatic Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Refractory Metastatic Melanoma Emerging Drugs
Neutral
Seeking Alpha
1 month ago
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent ruling, remain pending, which poses short-term headwinds. Nevertheless, BNTX's robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology.
Charts implemented using Lightweight Charts™